A breakthrough that could reshape cancer treatment. GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body’s own natural killer cells to identify and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company’s latest clinical progress and the potential of its lead drug candidate, GTB-3650. He also shares insights into the science behind TriKE®, the company’s pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide. Learn more about GT Biopharma: https://www.gtbiopharma.com/ Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIY And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia
